ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TRAIL R1

TRAIL R1

概要

Name:Tumor necrosis factor receptor superfamily member 10A
Target Synonym:TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,TRAILR-1,CD261,TNF-related apoptosis-inducing ligand receptor 1,Tumor Necrosis Factor Receptor Superfamily Member 10a Variant 2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
TR1-H5254 Human Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
TR1-H5254-structure
TR1-H5254-sds
TR1-H5228 Human Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag
TR1-H5228-structure
TR1-H5228-sds
ACRO Quality

生物活性データの一部

TR1-H5254-BLI
 TRAIL R1 BLI

Loaded Human TRAIL R1, Fc Tag (Cat. No. TR1-H5254) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.891 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TR1-H5254-BLI
 TRAIL R1 BLI

Loaded Human TRAIL, His Tag on HIS1K Biosensor, can bind Human TRAIL R1, Fc Tag (Cat. No. TR1-H5254) with an affinity constant of 2.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

カスタマーレビュー

Synonym Name

TNFRSF10A,TRAIL-R1,CD261,APO2,DR4

Background

Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aponermin Approved Beijing Shadong Biotech Co Ltd 沙艾特 Mainland China Multiple Myeloma Wuhan Hiteck Biological Pharma Co Ltd 2023-11-02 Multiple Myeloma Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Dulanermin (Shanghai GeBaiDe) Phase 3 Clinical Shanghai Gebaide Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) Phase 3 Clinical Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd Neoplasms Details
Rilunermin alfa SCB-313 (TRAIL-Trimer) Phase 1 Clinical Sichuan Sanyecao Bio-Pharmaceutical Co Ltd Hydrothorax; Ascites; Peritoneal Neoplasms; Pleural Effusion, Malignant Details
HLX56 HLX56; HLX-56 Phase 1 Clinical Shanghai Henlius Biotech Inc Solid tumours Details

This web search service is supported by Google Inc.

totopphone